Viaskin maker DBV Technologies will present eight abstract papers to the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Meeting in Atlanta, Georgia on March 3-6, 2017. The abstracts detail results of two-year follow-up data for viability testing of the Viaskin Phase IIb trial testing the long-term efficacy of the Viaskin Peanut treatment.
The trial followed patients for 36 months to evaluate the long-term effectiveness and safety of the Viaskin Peanut peanut allergy skin patch.
The Viaskin EPIT platform, if found effective for peanut allergy, could be quickly adapted to other food allergies.
DBV developed the EPIT platform for its skin patch, the company says, in order to create a modular delivery system that can be used with a variety of food allergens and proteins. The system delivers biologically active compounds into the immune system through the patient's skin. Evaluations for Viaskin Peanut are ongoing and global.
"The long-term clinical data we are presenting at AAAAI provide further insight into the promise of Viaskin Peanut as a potential treatment option for peanut-allergic children," said Dr. Lucia Septién, Chief Medical Officer of DBV Technologies. "These detailed results, combined with pre-clinical data that will be presented at the meeting, also underscore the tremendous potential of EPIT to help address a wide range of unmet medical needs."